Stocktoria
CHAMPIONS ONCOLOGY, INC. CSBR
CHAMPIONS ONCOLOGY, INC. (CSBR) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $59.4M at a -2.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.046 |
| Retained earnings / assets | -2.47 |
| EBIT / assets | 0.141 |
| Equity / liabilities | 0.132 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CSBR | CHAMPIONS ONCOLOGY, INC. | 5/9 | -7.27 | — | +4.4% |
| IVVD | Invivyd, Inc. | 2/9 | -0.36 | — | +110.5% |
| PLX | Protalix BioTherapeutics, Inc. | 2/9 | -11.01 | — | -1.2% |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| FENC | FENNEC PHARMACEUTICALS INC. | — | -4.88 | — | -6.1% |
About CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
FAQ
Is CSBR financially healthy?
CHAMPIONS ONCOLOGY, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CSBR pay a dividend?
No, CHAMPIONS ONCOLOGY, INC. does not currently pay a dividend.
How profitable is CSBR?
In FY2025, CHAMPIONS ONCOLOGY, INC. had a net margin of -2.0% and a return on equity of -28.9%.
Is CSBR overvalued or undervalued?
CHAMPIONS ONCOLOGY, INC. trades at about 15.0× trailing earnings — below its 10-year norm (10-year range 17.8×–936.0×, median 470.5×). Stocktoria reports the data, not buy/sell advice.
Is CSBR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CHAMPIONS ONCOLOGY, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.